Edesa Biotech año OPV
¿Qué es el año OPV de Edesa Biotech?
El año OPV de Edesa Biotech, Inc. es 2010
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech
¿Qué hace Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Empresas con año opv similar a Edesa Biotech
- Chigo tiene año OPV de 2009
- Jade Road Investments tiene año OPV de 2009
- Equity Metals tiene año OPV de 2009
- Kerr Mines tiene año OPV de 2009
- China e-Wallet Payment tiene año OPV de 2009
- SQS India BFSI tiene año OPV de 2009
- Edesa Biotech tiene año OPV de 2010
- Broken Hill Prospecting tiene año OPV de 2011
- Apollo Global Management Inc tiene año OPV de 2011
- Hipo Resources tiene año OPV de 2011
- Cogra 48 SA tiene año OPV de 2011
- New Mountain Finance Corp tiene año OPV de 2011
- Marfrig Global Foods SA tiene año OPV de 2011